Our findings not only highlight tRF-3021a as a promising diagnostic biomarker for CRC but also provide mechanistic insights for developing immunotherapeutic strategies targeting the MICA/NKG2D axis. This evidence concerns the gene KLRK1 and colorectal carcinoma.